Grifols SA (GRFS) Stock
GRFS has an Alpha Score of 51 out of 100 (weak), computed on Nov 9, 2026 from 3 of 4 sub-scores. 3 members of Congress disclosed 4 trades in GRFS since 2019: 1 purchase and 3 sales, most recently Daniel Goldman (sale, Mar 31, 2023). 3 of the hedge funds AlphaScala tracks reported GRFS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $30.94M. Its trailing P/E ratio is 13.2 and its net margin 6.1% (key statistics as of Oct 25, 2026).
What is GRFS's Alpha Score?
How it works →Alpha Score of 51 reflects moderate overall profile with moderate momentum, strong value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Grifols SA (GRFS)?
Most recent: Daniel Goldman (sale, Mar 31, 2023); records start Jun 24, 2019.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-03-31 | sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-02-27 | purchase | $1k – $15k |
| Greg Gianforte R-MT · House | 2019-11-11 | sale | $100k – $250k |
| Donna Shalala D-FL · House | 2019-06-24 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all GRFS political trades →Which hedge funds own GRFS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 4.37M | $30.94M | -13% |
| Citadel Ken Griffin | 114K | $806.7K | +437% |
| Point72 Steve Cohen | 26K | $182.6K | -50% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are GRFS's key statistics?
Key statistics as of Oct 25, 2026
How does GRFS's valuation compare with the Healthcare sector?
| Metric | GRFS | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 13.2 | 28.8 | 113 |
| Net margin | 6.09% | 3.66% | 170 |
| Return on equity | 8.43% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
GRFS price chart
Powered by TradingViewWhat does Grifols SA do?
Grifols S.A. is a Spanish multinational pharmaceutical and chemical manufacturer that operates internationally, focusing on innovative solutions in the health sector. The company is known for specializing in the production of plasma-derived medicines, transfusion medicine, and clinical diagnostics. Through its comprehensive expertise, Grifols contributes significantly to the biopharmaceutical industry, playing a crucial role in enhancing the quality of life for patients with chronic and rare diseases. The company's operations are divided into several key divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies, each contributing to its comprehensive healthcare offerings. Grifols’ expansive plasma donation network supports its vertically integrated business model, allowing for the efficient and sustainable production of life-saving products. Headquartered in Barcelona, it is a pivotal player in the healthcare market, enhancing healthcare delivery through biotechnology. Its presence spans across various countries, barely spanning critical industries such as transfusion medicine and biological products, where it continues to provide essential support for global health systems.